Target Name: CCT6A
NCBI ID: G908
Review Report on CCT6A Target / Biomarker Content of Review Report on CCT6A Target / Biomarker
CCT6A
Other Name(s): TCPZ | Acute morphine dependence-related protein 2 | amino acid transport defect-complementing | T-complex protein 1, zeta subunit | histidine transport regulator 3 | Cctz | Chaperonin containing TCP1, subunit 6A (isoform a) | TCP20 | TTCP20 | MoDP-2 | TCP-1-zeta | Tcp20 | CCT-zeta-1 | TCPZ_HUMAN | chaperonin containing TCP1, subunit 6A (zeta 1) | CCT6A variant 1 | Chaperonin containing TCP1 subunit 6A, transcript variant 1 | CCT-zeta | T-complex protein 1 subunit zeta (isoform a) | CCT-zeta;5 | HTR3 | T-complex protein 1 subunit zeta | chaperonin containing T-complex subunit 6 | acute morphine dependence related protein 2 | Chaperonin containing TCP1 subunit 6A | CCT6 | chaperonin containing TCP1 subunit 6A

CCT6A: A Potential Drug Target Or Biomarker for Cancer

CCT6A (TcPZ) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and gastrointestinal tract. It is a member of the Calbindin family of proteins, which are involved in cell signaling and cytoskeletal organization. Calbindin is a well-established biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the unique features of CCT6A is its ability to interact with the protein p21 (TcP21), which is a well-established cancer suppressor protein. When CCT6A is bound to p21, it can enhance the activity of p21 and lead to the inhibition of its negative effects on cell signaling pathways. This interaction between CCT6A and p21 suggests that CCT6A may be a potential drug target or biomarker for cancer.

In addition to its interaction with p21, CCT6A has also been shown to play a role in the regulation of cell adhesion and migration. It is involved in the formation of tight junctions, which are critical for the separation of tissues and the regulation of ion and solute transport. CCT6A has also been shown to be involved in the regulation of cell proliferation and apoptosis.

CCT6A is also expressed in various tissues that are sensitive to radiation damage, such as the skin and the gastrointestinal tract. This suggests that it may be a potential biomarker for radiation-induced DNA damage and its effects on cellular signaling pathways.

In conclusion, CCT6A is a protein that has been shown to interact with multiple proteins, including p21, and has been linked to various cellular signaling pathways. Its unique ability to enhance the activity of p21 and its involvement in the regulation of cell adhesion, migration, and apoptosis make it a potential drug target or biomarker for various diseases, including cancer. Further research is needed to fully understand the role of CCT6A in cellular signaling pathways and its potential as a drug or biomarker.

Protein Name: Chaperonin Containing TCP1 Subunit 6A

Functions: Component of the chaperonin-containing T-complex (TRiC), a molecular chaperone complex that assists the folding of proteins upon ATP hydrolysis (PubMed:25467444). The TRiC complex mediates the folding of WRAP53/TCAB1, thereby regulating telomere maintenance (PubMed:25467444). The TRiC complex plays a role in the folding of actin and tubulin (Probable)

The "CCT6A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCT6A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83